Skip to main content
Year archive

Swedish Orphan Biovitrum — 2018 filings

All 31 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2018, sourced directly from the official regulator.

31 Filings
2018 Period
2018 filings (31)
Filing Released Lang
Sobi™ förvärvar USA-rättigheterna till Synagis® från AstraZeneca – skapar en plattform för global tillväxt
M&A Activity
2018-11-13 Swedish
Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth
M&A Activity
2018-11-13 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-11-06 English
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-10-31 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-10-31 English
Results from the anaGO study – a phase 2 study with anakinra in patients with acute gout
Regulatory Filings
2018-10-03 English
Resultat från anaGO-studien - en fas 2 studie med anakinra i patienter med akut gikt
Earnings Release FY 2018
2018-10-03 Swedish
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2018-08-31 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Share Issue/Capital Change
2018-08-31 English
Sobi™ completes acquisition of the global rights for emapalumab from Novimmune
M&A Activity
2018-08-23 English
Sobi™ slutför förvärvet av de globala rättigheterna till emapalumab från Novimmune
M&A Activity
2018-08-23 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification
2018-07-23 English
Sobi™ strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune
Capital/Financing Update
2018-07-20 English
Sobi™ stärker inflammationsverksamheten genom förvärv av de globala rättigheterna till emapalumab från Novimmune
Regulatory Filings
2018-07-20 Swedish
The Board of directors exercises authorisation for repurchase of shares to secure the company’s commitments under the incentive programme
AGM Information
2018-07-18 English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Share Issue/Capital Change
2018-07-18 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2018-07-18 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q2 2018
2018-07-18 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-06-21 English
Kommuniké från Swedish Orphan Biovitrums (publ) (”Sobi”) årsstämma
AGM Information
2018-05-09 Swedish
Bulletin from Swedish Orphan Biovitrum’s (publ) (“Sobi’s”) Annual General Meeting (AGM)
AGM Information
2018-05-09 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-04-26 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-04-26 Swedish
Annual Report 2017
Annual Report FY 2017
2018-04-17 Swedish
Annual Report 2017
Annual Report FY 2017
2018-04-17 English
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information
2018-04-04 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information
2018-04-04 Swedish
Henrik Stenqvist is joining Sobi™ as new Chief Financial Officer
Board/Management Information
2018-02-26 English
Sobi™ utser Henrik Stenqvist till ny Chief Financial Officer
Board/Management Information
2018-02-26 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report FY 2017
2018-02-22 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report FY 2017
2018-02-22 English